MedTrace Logo

Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy

NCT05382988 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2022-05-19

No results posted yet for this study

Summary

Sodium zirconium cyclosilicate (SZC) has been demonstrated for its serum potassium-lowering efficacy and safety in hyperkalemia hemodialysis patients.

However, the effects of SZC during the perioperative period remained unknown.

This experiment aimed to determine whether using SZC would impact the serum potassium levels in patients with maintenance hemodialysis after parathyroidectomy (PTX).

Conditions

  • Sodium Zirconium Cyclosilicate
  • Hyperkalemia
  • Hyperparathyroidism, Secondary

Interventions

DRUG

Sodium zirconium cyclosilicate

The experimental group was required to take SZC 10g at 6 am on the day of surgery.

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Shuangxin Liu, Ph.D · Guangdong Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2021-12-31
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382988 on ClinicalTrials.gov